Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 4.73
TROV's Cash-to-Debt is ranked higher than
54% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. TROV: 4.73 )
Ranked among companies with meaningful Cash-to-Debt only.
TROV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 4.41 Max: No Debt
Current: 4.73
Equity-to-Asset 0.28
TROV's Equity-to-Asset is ranked lower than
87% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TROV: 0.28 )
Ranked among companies with meaningful Equity-to-Asset only.
TROV' s Equity-to-Asset Range Over the Past 10 Years
Min: -9.76  Med: 0.46 Max: 0.75
Current: 0.28
-9.76
0.75
Debt-to-Equity 0.47
TROV's Debt-to-Equity is ranked lower than
61% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. TROV: 0.47 )
Ranked among companies with meaningful Debt-to-Equity only.
TROV' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.47  Med: 0.47 Max: 1.79
Current: 0.47
-0.47
1.79
Debt-to-EBITDA -0.05
TROV's Debt-to-EBITDA is ranked lower than
99.99% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. TROV: -0.05 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TROV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.02  Med: -0.44 Max: -0.05
Current: -0.05
-1.02
-0.05
Piotroski F-Score: 3
Altman Z-Score: -25.55
Beneish M-Score: -3.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -10090.40
TROV's Operating Margin % is ranked lower than
99% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TROV: -10090.40 )
Ranked among companies with meaningful Operating Margin % only.
TROV' s Operating Margin % Range Over the Past 10 Years
Min: -10537.01  Med: -4127.8 Max: -1077.56
Current: -10090.4
-10537.01
-1077.56
Net Margin % -10391.24
TROV's Net Margin % is ranked lower than
99% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. TROV: -10391.24 )
Ranked among companies with meaningful Net Margin % only.
TROV' s Net Margin % Range Over the Past 10 Years
Min: -10391.24  Med: -4560.23 Max: -867.83
Current: -10391.24
-10391.24
-867.83
ROE % -197.25
TROV's ROE % is ranked lower than
93% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. TROV: -197.25 )
Ranked among companies with meaningful ROE % only.
TROV' s ROE % Range Over the Past 10 Years
Min: -197.25  Med: -102.41 Max: -96.39
Current: -197.25
-197.25
-96.39
ROA % -91.89
TROV's ROA % is ranked lower than
88% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. TROV: -91.89 )
Ranked among companies with meaningful ROA % only.
TROV' s ROA % Range Over the Past 10 Years
Min: -1064.26  Med: -67.95 Max: -51.11
Current: -91.89
-1064.26
-51.11
ROC (Joel Greenblatt) % -888.42
TROV's ROC (Joel Greenblatt) % is ranked lower than
83% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. TROV: -888.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TROV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -17351.61  Med: -2344.73 Max: -888.42
Current: -888.42
-17351.61
-888.42
3-Year Revenue Growth Rate -4.70
TROV's 3-Year Revenue Growth Rate is ranked lower than
71% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. TROV: -4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TROV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -29.3  Med: -21.9 Max: -4.7
Current: -4.7
-29.3
-4.7
3-Year EBITDA Growth Rate 23.40
TROV's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. TROV: 23.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TROV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.9  Med: 12.8 Max: 51
Current: 23.4
-2.9
51
3-Year EPS without NRI Growth Rate 25.10
TROV's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. TROV: 25.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TROV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 17.95 Max: 56.4
Current: 25.1
-3.5
56.4
GuruFocus has detected 3 Warning Signs with TrovaGene Inc TROV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TROV's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

TROV Guru Trades in Q4 2015

First Eagle Investment 376,111 sh (New)
» More
Q1 2016

TROV Guru Trades in Q1 2016

First Eagle Investment Sold Out
» More
Q1 2017

TROV Guru Trades in Q1 2017

Jim Simons 29,124 sh (New)
» More
Q2 2017

TROV Guru Trades in Q2 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621512    SIC: 8071
Compare:XKRX:221800, XKRX:058110, XPAR:ALTER, XKRX:246250, NAS:SLNO, OTCPK:DCTH, XKRX:214610, OTCPK:PRLX, NAS:BIOP, TSXV:SVA, OTCPK:INIS, ASX:IBX, ROCO:4160, NAS:CBMX, NAS:IDXG, ASX:GSS, NAS:CHEK, NAS:HTGM, XKRX:109820, OSL:NATTO » details
Traded in other countries:XE7A.Germany,
Headquarter Location:USA
TrovaGene Inc is a life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing.

TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology. Its primary focus is to utilize its technology in measuring circulating tumor DNA (deoxyribonucleic acid) in urine and blood with its proprietary platforms and research. The company has developed Trover liquid biopsy tests for use by physicians, third-party clinical laboratories, and pharmaceutical companies. It operates its business through one business segment of developing of molecular genetic detection technology.

Top Ranked Articles about TrovaGene Inc

Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells
FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
Trovagene Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Trovagene, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines
Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy
Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results
Trovagene, Antonius Schuh and Stephen Zaniboni Resolve Employment Dispute
Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia

Ratios

vs
industry
vs
history
PB Ratio 7.70
TROV's PB Ratio is ranked lower than
72% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. TROV: 7.70 )
Ranked among companies with meaningful PB Ratio only.
TROV' s PB Ratio Range Over the Past 10 Years
Min: 1.88  Med: 6.1 Max: 70.71
Current: 7.7
1.88
70.71
PS Ratio 79.09
TROV's PS Ratio is ranked lower than
95% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. TROV: 79.09 )
Ranked among companies with meaningful PS Ratio only.
TROV' s PS Ratio Range Over the Past 10 Years
Min: 59.09  Med: 278.57 Max: 916.43
Current: 79.09
59.09
916.43
EV-to-EBIT -0.74
TROV's EV-to-EBIT is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. TROV: -0.74 )
Ranked among companies with meaningful EV-to-EBIT only.
TROV' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.7  Med: -5.6 Max: -0.2
Current: -0.74
-24.7
-0.2
EV-to-EBITDA -0.76
TROV's EV-to-EBITDA is ranked lower than
99.99% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. TROV: -0.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
TROV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.8  Med: -5.6 Max: -0.2
Current: -0.76
-24.8
-0.2
EV-to-Revenue 73.76
TROV's EV-to-Revenue is ranked lower than
94% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. TROV: 73.76 )
Ranked among companies with meaningful EV-to-Revenue only.
TROV' s EV-to-Revenue Range Over the Past 10 Years
Min: 22.2  Med: 230.6 Max: 1001.5
Current: 73.76
22.2
1001.5
Current Ratio 1.16
TROV's Current Ratio is ranked lower than
85% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. TROV: 1.16 )
Ranked among companies with meaningful Current Ratio only.
TROV' s Current Ratio Range Over the Past 10 Years
Min: 0.08  Med: 7.8 Max: 20.57
Current: 1.16
0.08
20.57
Quick Ratio 1.16
TROV's Quick Ratio is ranked lower than
77% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TROV: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
TROV' s Quick Ratio Range Over the Past 10 Years
Min: 0.08  Med: 7.8 Max: 20.57
Current: 1.16
0.08
20.57
Days Sales Outstanding 161.88
TROV's Days Sales Outstanding is ranked lower than
86% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. TROV: 161.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
TROV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.3  Med: 111.33 Max: 161.88
Current: 161.88
74.3
161.88
Days Payable 111.95
TROV's Days Payable is ranked higher than
74% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. TROV: 111.95 )
Ranked among companies with meaningful Days Payable only.
TROV' s Days Payable Range Over the Past 10 Years
Min: 111.95  Med: 604.08 Max: 18201.33
Current: 111.95
111.95
18201.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.60
TROV's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. TROV: -17.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TROV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.2  Med: -22.55 Max: -17.6
Current: -17.6
-38.2
-17.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 7.91
TROV's Price-to-Tangible-Book is ranked lower than
56% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.57 vs. TROV: 7.91 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TROV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.08  Med: 6.26 Max: 63.88
Current: 7.91
3.08
63.88
Price-to-Median-PS-Value 0.28
TROV's Price-to-Median-PS-Value is ranked higher than
93% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. TROV: 0.28 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TROV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25  Med: 1.03 Max: 2.6
Current: 0.28
0.25
2.6
Earnings Yield (Greenblatt) % -136.63
TROV's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. TROV: -136.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TROV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -504.3  Med: -17.9 Max: -4.1
Current: -136.63
-504.3
-4.1

More Statistics

Revenue (TTM) (Mil) $0.35
EPS (TTM) $ -1.25
Beta-0.40
Short Percentage of Float8.84%
52-Week Range $0.61 - 4.30
Shares Outstanding (Mil)37.27

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 0 1 1 2
EPS ($) -0.95 -0.77 -0.69 -0.65
EPS without NRI ($) -0.95 -0.77 -0.69 -0.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}